T1	Participants 0 82	Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma
T2	Participants 231 367	patients with resected renal cell carcinoma (RCC) at high risk for recurrent disease (TNM stages III and IV resected distant metastases)
T3	Participants 390 473	Patients with surgically resected locally advanced (T3-4 or N1-2) or metastatic RCC
T4	Participants 1081 1160	Forty-one patients were entered in the study and 40 were evaluable for toxicity
